PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcas ...

Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in mu ...

With a market cap of $15.1 billion, Viatris Inc. (VTRS) is a global healthcare company operating across North America, Europe, Asia-Pacific, Africa, Latin America, and the Middle East, delivering a broad portfolio of branded, generic, complex, and biosimilar medicines. Through its four regional segments, the company serves multiple therapeutic areas and distributes its products worldwide via diverse pharmacy and healthcare channels. Shares of the Canonsburg, Pennsylvania-based company have slightly outpe ...

Company Overview - Viatris Inc. (VTRS) is a global pharmaceutical and healthcare company with a market cap of $14.6 billion, formed in November 2020 and headquartered in Canonsburg, Pennsylvania. The company develops, manufactures, and distributes a wide range of generic, branded, complex generic, and biosimilar medicines across more than 165 countries, serving approximately 1 billion patients annually [1]. Earnings Expectations - Analysts anticipate that VTRS will report a profit of $0.53 per share on a diluted basis for fiscal 2025 fourth-quarter earnings, reflecting a decrease of 1.9% from $0.54 per share in the same quarter last year. The company has exceeded consensus estimates in three of the last four quarters while missing on one occasion [2]. - For the full fiscal year 2025, analysts expect VTRS to report earnings per share (EPS) of $2.33, which is a decline of 12.1% from $2.65 in fiscal 2024. However, EPS is projected to increase by 6.4% year over year to $2.48 in fiscal 2026 [3]. Stock Performance - VTRS stock has increased by 15.2% over the past year, outperforming the S&P 500 Index's gain of 13.7% and the Health Care Select Sector SPDR Fund's increase of 11.1% during the same period [4]. Product Launch - On January 20, Viatris launched its heart failure treatment, Inpefa (sotagliflozin), in the United Arab Emirates, marking its first commercial launch in international markets. Inpefa is the first dual SGLT1/2 inhibitor approved for heart failure, aimed at reducing the risk of cardiovascular death and related hospitalizations, thereby enhancing Viatris' cardiovascular portfolio and innovative pipeline. Following the announcement, VTRS shares rose by 3.1% in the subsequent trading session [5]. Analyst Ratings - The consensus opinion on VTRS stock is cautious, with an overall "Moderate Buy" rating. Among ten analysts covering the stock, four recommend a "Strong Buy," five suggest a "Hold," and one advises a "Moderate Sell." VTRS is currently trading above its average analyst price target of $13 [6].

Core Insights - Viatris has launched Inpefa (sotagliflozin) in the UAE, marking the first commercialization of this treatment in its territories, with plans for future launches in multiple countries to expand access outside the U.S. and Europe [1][3] Product Overview - Inpefa is the first and only dual SGLT1/2 inhibitor approved for heart failure treatment, aimed at reducing cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors [2][6] - The approval of Inpefa is based on two pivotal Phase 3 trials, SOLOIST-WHF and SCORED, which enrolled over 11,800 patients globally, demonstrating significant reductions in major cardiovascular events [3][5] Clinical Efficacy - In the SOLOIST-WHF trial, Inpefa reduced the composite risk of heart failure hospitalization, urgent visits, and cardiovascular death by 33% compared to placebo, with benefits increasing to 51% when initiated prior to discharge [3] - In the SCORED trial, Inpefa achieved a 25% reduction in the same composite endpoint among patients with type 2 diabetes and chronic kidney disease [3] - The treatment also showed a 23% reduction in major adverse cardiovascular events (MACE), with significant reductions in myocardial infarction (32%) and stroke (34%) [3] Market Context - Heart failure is the leading cause of hospitalization globally, affecting over 64 million people, with substantial post-discharge mortality and readmission rates [4] - The 30-day post-discharge mortality rate is approximately 6.7%, with readmission rates averaging 13%, increasing to 23% mortality and 36% readmission at one year post-discharge [4] Company Strategy - Viatris aims to expand its innovative portfolio in cardiovascular diseases, leveraging its scientific leadership and commercial legacy [3][9] - The company has submitted regulatory filings for Inpefa in several countries, including Canada, Australia, and Mexico, and plans to broaden global submissions in the coming years [3][9]

Company Overview - Viatris operates as three distinct businesses: a global generics company, an established brands company with iconic brands, and an emerging innovative brands platform [3] Financial Performance - In the last 12 months, Viatris generated $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in adjusted EBITDA [4] - The company reported $2.2 billion in free cash flow and $2.32 billion in adjusted EBITDA [4] Global Reach - Viatris operates in 165 countries and offers 1,400 unique products [4] - The company provides medicine to over 1 billion people annually, highlighting its significant impact on global health [4]

Summary of Viatris Conference Call Company Overview - Viatris operates as three distinct businesses: a global generics company, an established brands company, and an emerging innovative brands platform [2][3] - The company reported $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in free cash flow over the last 12 months [2] Key Financial Highlights - Viatris delivered $14.1 billion in revenue and $4.1 billion in EBITDA [2] - Achieved $2.32 in adjusted EBITDA and $2.2 billion in free cash flow [2] - The company operates in 165 countries with 1,400 unique products, serving over 1 billion people annually [3] Strategic Developments - The company advanced its pipeline with five positive phase 3 readouts out of six [4] - Significant progress was made with Cenerimod, Selatogrel, and Lucerastat in their phase 3 programs [4] - Over $1 billion was returned to shareholders through dividends and share buybacks [4] - Conducted 60 regional business development deals to support the base business, particularly in Japan [4][5] Future Outlook - Anticipated high-value product launches in 2026, including Sotagliflozin, Phentolamine, and Effexor GAD [6][7] - The company expects to generate significant cash flow in 2026, with plans for continued shareholder returns and growth asset development [9] - A strategic review is expected to yield substantial savings and reinvestment opportunities [22][24] Market Dynamics - The company is focusing on the U.S. market for high-margin revenue-generating assets, while also revitalizing its portfolio in Japan [36] - The competitive landscape is favorable for acquiring assets in the $500 million-$1 billion revenue range, with less competition for these assets [20][21] Pipeline and Product Development - Positive phase 3 results for Cenerimod and Selatogrel are expected to lead to significant market opportunities [51][60] - Fast-Acting Meloxicam is positioned to address the opioid crisis in pain management, with a strong market potential [43][45] - Selatogrel aims to revolutionize acute myocardial infarction management, with a large patient population and significant unmet need [60][62] Challenges and Risks - Pricing pressures and policy adjustments are anticipated in the JANS business, along with generic competition in Japan [29] - The Indore facility's remediation is nearing completion, with limited expected volatility in 2026 numbers [30][32] Capital Allocation Strategy - The company plans a balanced approach to capital allocation, focusing on shareholder returns and business development [34] - Expected free cash flow of over $2 billion annually for the next five years [33] Conclusion - Viatris is positioned for sustainable growth with a strong pipeline, strategic acquisitions, and a focus on enhancing its core business while navigating market challenges [12][15]

44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1 Non-GAAP Financial Measures This presentation includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, adjusted EBITDA, free cash flow, free cash flow excluding transaction-related costs, and adjusted EPS, are presented in order to supplement inv ...

Core Insights - Viatris Inc. has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer to enhance the company's culture and stakeholder communication strategies during its transformation efforts [1][5]. Company Overview - Viatris is a global healthcare company that aims to bridge the gap between generics and brand-name medications, providing access to high-quality medicines for approximately 1 billion patients annually [6]. Leadership and Experience - Lara Ramsburg brings over 25 years of experience in building effective cross-functional teams and strategic communication, having held various executive roles at Viatris and its legacy company, Mylan [2][3]. - In her new role, Ramsburg will oversee global talent, total rewards, employee experience, people solutions, and HR business partner teams, in addition to her existing responsibilities in Corporate Affairs [3]. Strategic Importance - The appointment of Ramsburg is seen as crucial for maintaining employee engagement, wellbeing, and growth as the company prepares for its next stage of growth [5].

Core Viewpoint - Viatris (VTRS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, with institutional investors using these estimates to determine fair value [4][6]. Company Performance and Investor Sentiment - The upgrade in Viatris' rating signifies an improvement in the company's underlying business, which is expected to positively influence its stock price [5][10]. - Over the past three months, the Zacks Consensus Estimate for Viatris has increased by 2.2%, with expected earnings of $2.32 per share for the fiscal year ending December 2025, unchanged from the previous year [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - Viatris' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9][10].